QIAGEN announced a decision to discontinue the NeuMoDx 96 and 288 Molecular Systems in light of the market development trends for these product lines following the COVID-19 pandemic and changing customer needs for integrated PCR-based clinical molecular testing systems. This decision will allow QIAGEN to refocus resources and efforts on developing and commercializing other innovative solutions within its portfolio, in particular the QIAstat-Dx system for syndromic testing, the QIAcuity portfolio of digital PCR systems and the QIAGEN Digital Insights (QDI) bioinformatics business. These are complemented by QIAGEN building on proven leadership positions in Sample technologies and the QuantiFERON-TB franchise. QIAGEN understands the impact of this decision on its customers and will continue to provide support for existing NeuMoDx users during a transition period into 2025.

This includes ongoing maintenance, technical support, and the provision of necessary consumables for a specified period. Support will also be offered in helping customers transition to other solutions.